Real-World Evidence on the Early Effects of Golimumab on Work Productivity and Activity Impairment in Patients with Spondyloarthritis: Interim Results from a Prospective, Observational Study

Panagiotis Athanassiou ¹, Ioannis Kallitsakis ², Gkikas Katsifis ³, Anastasios Kotrotsios ⁴, Georgios Vosvotekas ⁵, Panagiotis Georgiou ⁶, Andreas Bounas ⁷, Yiannis Haratsis ⁸, Evangelia Petrikkou ⁸ and Dimitrios Vassilopoulos⁹, ¹General Hospital of Thessaloniki “Agios Pavlos”, Thessaloniki, Greece, ²Private Practice, Chania, Greece, ³Naval Hospital of Athens, Rheumatology Clinic, Athens, Greece, ⁴Private Practice, Karditsa, Greece, ⁵Euromedica General Clinic of Thessaloniki, Rheumatology Clinic, Thessaloniki, Greece, ⁶General Hospital of Patras “Agios Andreas”, Patras, Greece, ⁷Olympion therapeutirion, Patras, Greece, ⁸Merck Sharp & Dohme Pharmaceutical, Industrial and Commercial S.A, Medical Affairs, Athens, Greece, ⁹2nd Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, Hippokration General Hospital, Athens, Greece

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: anti-TNF therapy, patient outcomes, Rheumatoid arthritis (RA), Work Disability and seronegative spondyloarthropathy

Session Information

Date: Sunday, November 10, 2019

Title: Patient Outcomes, Preferences, & Attitudes Poster I: Patient Reported Outcomes

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: There are limited real life data regarding the effect of golimumab on work productivity and activity impairment in rheumatic diseases. The aim of our study was to evaluate these work-related patient reported outcomes (PROs) in spondyloarthritis (SpA) patients treated with golimumab in daily clinical practice.

Methods: This is a 12-month multicenter, non-interventional, prospective study of working adults with active axial SpA (axSpA) or psoriatic arthritis (PsA) treated with golimumab. Prospectively collected data regarding work productivity and activity impairment (using the specific health problem WPAI:SHP instrument) from the first 60 patients who completed the 3-month visit (or were prematurely withdrawn prior to 3 months) are reported here.

Results: Sixty patients, 34 (56.7%) with axSpA and 26 (43.3%) with PsA were enrolled over a 7.7-month recruitment period (from 06-Apr-2017 to 27-Nov-2017) by 10 public/private sector hospitals and 3 private offices in Greece. Fifty-nine patients attended the 3-month visit, while one patient was withdrawn 12.1 weeks after enrollment due to golimumab discontinuation for lack of therapeutic response. The overall SpA population included 47% males with a mean age of 44.8 years at enrollment. Overall, 23% of patients had previously received biologics, while 31.7% were receiving concomitant conventional disease-modifying antirheumatic drugs (csDMARDs) during the study period. At baseline, the mean DAS28-ESR of the overall SpA population was 4±1.2, while the mean BASDAI score among axSpA patients was 5.8±1.8 In the overall SpA population, 72.9% (43/59), 91.4% (53/58), 94.9% (56/59), and 96.7% (58/60) of patients, reported absenteeism, presenteeism, work productivity loss, and activity impairment due to SpA, respectively, at baseline. At 3 months the respective rates were 46.4% (26/56), 89.3% (50/56), 91.1% (51/56), and 88.3% (53/60). In the overall SpA population, the median scores for absenteeism, presenteeism, work productivity loss, and activity impairment significantly decreased (p< 0.001 for all) by 5.7%, 40.0%, 38.1%, and 40.0%, respectively (Figure 1).

Conclusion: Actively working patients with SpA treated with golimumab in real life settings demonstrated significant improvements in all domains of the work-related PROs as early as 3 months after treatment initiation. These preliminary data, if confirmed at 6 and 12 months, provide valuable work-related information on the effect of a golimumab treatment of SpA patients in real life practice.

Fig 1

WPAI outcomes at baseline and at 3 months post-baseline in the SpA population

Disclosure: P. Athanassiou, None; I. Kallitsakis, None; G. Katsifis, ABBVIE, 5, 8, AENORASIS, 5, 8, GENESIS PHARMA, 5, 8, JANSSEN, 5, 8, MSD, 5, 8, NOVARTIS, 5, 8, UCB, 5, 8, PFIZER, 5, 8, ROCHE, 5, 8; A. Kotrotsios, None; G. Vosvotekas, None; P. Georgiou, None; A. Bounas, AbbVie, 5, 8, BMS, 5, 8, MSD, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Roche, 5, 8; Y. Haratsis, MSD, 3; E. Petrikkou, MSD, 3, 4, BRISTOL MEYERS SQUIBB, 4; D. Vassilopoulos, None.

To cite this abstract in AMA style:

Athanassiou P, Kallitsakis I, Katsifis G, Kotrotsios A, Vosvotekas G, Georgiou P, Bounas A, Haratsis Y, Petrikkou E, Vassilopoulos D. Real-World Evidence on the Early Effects of Golimumab on Work Productivity and Activity Impairment in Patients with Spondyloarthritis: Interim Results from a Prospective, Observational Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/real-world-evidence-on-the-early-effects-of-golimumab-on-work-productivity-and-activity-impairment-in-patients-with-spondyloarthritis-interim-results-from-a-prospective-observational-study/. Accessed .

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/real-world-evidence-on-the-early-effects-of-golimumab-on-work-productivity-and-activity-impairment-in-patients-with-spondyloarthritis-interim-results-from-a-prospective-observational-study/